Enasinib 50 mg (Enasidenib) Tablet: Global Patient Access, Price, & Clinical Safety Guide

Enasinib is an oral, targeted small-molecule inhibitor of the isocitrate dehydrogenase-2 (IDH2) enzyme. It is specifically indicated for the treatment of adult patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) who harbor a confirmed isocitrate dehydrogenase-2 (IDH2) mutation, as detected by an FDA-approved diagnostic test. As a first-in-class differentiation therapy, Enasinib works by reducing levels of the oncometabolite 2-hydroxyglutarate (2-HG), thereby restoring normal myeloid cellular differentiation and reducing the blast count.

Clinically AML Patient Management Experience by Medical Reviewer

“For decades, the management of relapsed or refractory AML was limited to intensive salvage chemotherapy, which often yielded poor outcomes and significant toxicity, especially in older populations. The identification of IDH2 mutations—present in approximately 8% to 15% of AML cases—marked a turning point.

In my clinical experience, the transition from broad-spectrum cytotoxic agents to targeted inhibitors like Enasidenib has fundamentally altered how we approach R/R disease. Unlike traditional chemo, Enasinib does not work through immediate marrow ablation; it forces malignant blasts to mature into functional neutrophils. This ‘differentiation’ approach requires a different mindset regarding response assessment and side-effect management, particularly concerning Differentiation Syndrome. The availability of high-quality generic equivalents through manufacturers like Everest Pharmaceutical is critical. It bridges the gap between clinical innovation and global patient access, ensuring that life-extending targeted therapy is not restricted by geography or socioeconomic barriers.” (Dr. Salma Elreedy)

Specific Indications, Dosage, Side Effects, Clinical Efficacy, Adverse Event Management Profile

Precise Indications & Biomarker Requirements Mentioned in the FDA

Enasinib is not a frontline treatment for all AML patients. Efficacy is strictly tied to the presence of IDH2 mutations (specifically the R140 or R172 variants).

• Companion Diagnostic: Testing must be performed using a validated assay (e.g., Abbott RealTime IDH2 assay) on blood or bone marrow samples.
• Indication: Treatment of adult patients with R/R AML with an IDH2 mutation.

Mechanism of Action & Pharmacokinetics (ADME)

Enasidenib targets the mutant IDH2 enzyme to inhibit the conversion of alpha-ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG).

• Absorption: Peak plasma concentration reached in roughly 4 hours. Steady-state is achieved within 29 days.
• Distribution: High protein binding (98.5%).
• Metabolism: Primarily metabolized via CYP3A4, CYP2C19, and UGT enzymes.
• Excretion: 89% eliminated in feces; 11% in urine.
• Half-life: Approximately 137 hours, requiring careful monitoring during dose adjustments.

Dosage & Adverse Event (AE) Management

The standard starting dose is 100 mg orally once daily (utilizing two 50 mg tablets) until disease progression or unacceptable toxicity.

Clinical Efficacy & Real-World Evidence (RWE)

The efficacy of Enasidenib was established in trial AG221-C-001 (NCT01915498), a multi-center, open-label study:

• Complete Remission (CR) / CR with partial hematologic recovery (CRh): 23%
• Median Duration of CR/CRh: 8.2 months.
• Median Time to First Response: 1.9 months (responses can take up to 6 months).
• Overall Survival (OS): Median OS in the R/R population was approximately 9.3 months.

Real-World Evidence (RWE): Post-marketing data suggests that in community settings, patients often remain on therapy longer than in trials, provided Differentiation Syndrome is managed aggressively in the first 60 days. RWE indicates that transfusion independence is achieved in approximately 34% of patients who do not reach a full CR.

Drug-Drug Interaction (DDI) Matrix

Precautions & Special Populations

• Embryo-Fetal Toxicity: Enasinib can cause fetal harm. Both females of reproductive potential and males with female partners should use effective contraception during treatment and for 2 months after the final dose. (as Enasidenib may interfere with hormonal birth control).
• Lactation: Advise patients not to breastfeed during treatment and for 1 month after the final dose.
• Pediatric Use: Safety and efficacy have not been established in patients under 18.
• Geriatric Use: No significant differences in safety or efficacy observed in patients ≥ 65 years.
• Storage: Store at 20°C to 25°C (68°F to 77°F). Keep in original bottle with desiccant to protect from moisture.

Manufacturing Quality Assurance, Named Patient Global Access, & Brand Comparison

Everest Pharmaceuticals Manufacturing Insights

Everest Pharmaceutical operates advanced manufacturing facilities that adhere to World Health Organization Good Manufacturing Practices (WHO-GMP). Each batch of Enasinib undergoes stringent quality control, including High-Performance Liquid Chromatography (HPLC) for purity assessment and dissolution profiling to ensure therapeutic equivalence to the originator.

Global Access via Named Patient Program (NPP)

For patients in regions where Enasinib is not yet locally registered, it can be accessed through the Named Patient Program (NPP). This legal framework allows for the importation of life-saving medications.

1. Prescription: A valid prescription from a local licensed oncologist.
2. Medical Necessity: A Letter of Medical Necessity (LMN) stating the patient’s IDH2 mutation status and treatment history.
3. Import License: Application for a personal-use import permit from the local Ministry of Health.
4. Documentation: Submission of patient ID and relevant clinical reports.

Originator (IDHIFA) vs Generic (Enasinib)

Frequently Asked Questions (FAQs)